Cytokinetics Receives 2.9M from NINDS to Help Advance Development of CK-2017357

Cytokinetics, Inc announced recently that the National Institute of Neurological Disorders and Stroke (NINDS) awarded the company $2.9 million to support research and development of CK-2017357, their fast skeletal muscle troponin activator currently in Phase II trials for ALS, for the potential treatment of the rare neuromuscular disease myasthenia gravis.

Click here to read more.

Share this: